AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Stocktitan

Published November 13, 2026 · Updated November 14, 2026

Enveric Biosciences Q3 2026 loss narrows to $2.5M | ENVB 8-K Filing - Stock Titan

Read the full story at Stocktitan

psychedelic and psychedelic -inspired ... Disclosure of earnings results, typically an earnings press release or preliminary financials.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release